March 2, 2010 (FinancialWire) — GeoVax Labs, Inc. (OTCBB: GOVX), biopharmaceutical firm, said it intends to file a registration statement for the sale of $20 million or more of its common stock.

The offering may also include shares to be sold by selling stockholders, although no arrangements have been made. The purpose of the offering would be to raise funds to enable the company to develop its vaccines business.

Georgia-based GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV-1 and other infectious agents.

The company’s goals include developing AIDS vaccines for global markets, manufacturing and testing these vaccines under GMP/GLP conditions, conducting phase 1, 2 and 3 human trials for vaccine safety and effectiveness, and obtaining regulatory approval of these vaccines in the USA and specified international markets.

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.